Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
Clinical trial NCT01677572 · TERMINATED
Trial details
- NCT number
- NCT01677572
- Sponsor
- Biogen
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2012-10-05
- Primary completion
- 2019-07-31
- Enrollment
- 197
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.